NewLink Genetics Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Ames IA United States (1999)
Status: Defunct (2023)

Organization Overview

First Clinical Trial
2003
NCT00073398
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NewLink Genetics Corporation | NewLink Genetics Inc | NewLink Genetics Incorporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Large Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Ependymoma (Phase 1)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Gliosarcoma (Phase 2)

Hemorrhagic Fever, Ebola (Phase 1)

Kidney Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 3)

Medulloblastoma (Phase 1)

Melanoma (Phase 3)

Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 44
  • # of Trial APIs: 32